GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (CHIX:PHARMa) » Definitions » EV-to-EBITDA

Pharming Group (CHIX:PHARMA) EV-to-EBITDA : 36.42 (As of Jun. 03, 2025)


View and export this data going back to 2008. Start your Free Trial

What is Pharming Group EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Pharming Group's enterprise value is €707.9 Mil. Pharming Group's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was €19.4 Mil. Therefore, Pharming Group's EV-to-EBITDA for today is 36.42.

The historical rank and industry rank for Pharming Group's EV-to-EBITDA or its related term are showing as below:

CHIX:PHARMa' s EV-to-EBITDA Range Over the Past 10 Years
Min: -855.62   Med: 12.7   Max: 178.99
Current: 36.42

During the past 13 years, the highest EV-to-EBITDA of Pharming Group was 178.99. The lowest was -855.62. And the median was 12.70.

CHIX:PHARMa's EV-to-EBITDA is ranked worse than
82.56% of 493 companies
in the Biotechnology industry
Industry Median: 8.54 vs CHIX:PHARMa: 36.42

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-06-03), Pharming Group's stock price is €0.8708. Pharming Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was €-0.019. Therefore, Pharming Group's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Pharming Group EV-to-EBITDA Historical Data

The historical data trend for Pharming Group's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group EV-to-EBITDA Chart

Pharming Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.20 11.03 21.26 72.15 36.98

Pharming Group Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 78.75 122.33 75.60 36.98 27.97

Competitive Comparison of Pharming Group's EV-to-EBITDA

For the Biotechnology subindustry, Pharming Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharming Group's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharming Group's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Pharming Group's EV-to-EBITDA falls into.


;
;

Pharming Group EV-to-EBITDA Calculation

Pharming Group's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=707.899/19.438
=36.42

Pharming Group's current Enterprise Value is €707.9 Mil.
Pharming Group's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €19.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharming Group  (CHIX:PHARMa) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Pharming Group's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.8708/-0.019
=At Loss

Pharming Group's share price for today is €0.8708.
Pharming Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.019.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Pharming Group EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Pharming Group's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharming Group Business Description

Address
Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Pharming Group Headlines

No Headlines